EUVIMEDEUVIMED entdecken
Crossref

Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis

Yoshitomo Yanagimoto, Kazuyoshi Yamamoto, Kei Yamamoto, Yasunori Masuike, Yuki Ushimaru, Takeshi Omori, Daisuke Sakai, Toshihiro Kudo, Norihiro Matsuura, Takahito Sugase, Takashi Kanemura, Ryota Mori und 11 weitere

Cancer Chemotherapy and Pharmacology · 20.07.2026 · 96 (1)

DOI: 10.1007/s00280-026-04927-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 20.07.2026. Verfasst von Yoshitomo Yanagimoto und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567 , Japan. yoshitomo-0225@out…. Hauptthemen laut MEDLINE: Hypoalbuminemia, Stomach Neoplasms, Gastric Mucosa, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zolbetuximab plus chemotherapy is standard first-line therapy for HER2-negative, CLDN18.2-positive advanced gastric or gastroesophageal junction cancer (GC/GEJC), but the incidence, course, and clinical correlations of zolbetuximab-related gastric mucosal injury and hypoalbuminemia remain unclear. We thus evaluated these relationships and the clinical course in real-world practice. We retrospectively analyzed 38 patients with HER2-negative, CLDN18.2-positive, advanced GC/GEJC treated with zolbetuximab plus chemotherapy at a single center. Associations between endoscopic findings and albumin changes from baseline were analyzed. Median albumin decreased from 3.7 to 2.6 g/dL. The median albumin decline was greater in patients without gastrectomy (− 1.0 g/dL) or with partial gastrectomy (− 1.1 g/dL) than in those with total gastrectomy (− 0.3 g/dL; P = 0.009 and 0.007). Albumin levels fell rapidly at weeks 1–3 and recovered toward baseline by weeks 19–27. Upper gastrointestinal endoscopies were performed in patients with a remaining stomach, showing peak abnormalities within 7–12 weeks; no cases with grade ≥ 2 gastric mucosal injury were observed after week 25. White exudate was associated with albumin decline (− 0.9 vs. −0.4 g/dL, P = 0.023). The presence of white exudate demonstrated a significant association with a marked decrease in serum albumin levels. The risk of hypoalbuminemia appeared to be lower in patients after total gastrectomy. Serum albumin levels decreased after treatment initiation and subsequently showed a tendency to recover over time. Gastric mucosal abnormalities were most frequently observed during the early phase of treatment and were less common in examinations performed after week 25.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypoalbuminemiaStomach NeoplasmsGastric MucosaAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedGastrectomyAdultSerum AlbuminEsophagogastric JunctionAged, 80 and over

Stichwörter der Autor:innen

Gastric CancerGastritisGastroesophageal junction cancerHypoalbuminemiaWhite exudatesZolbetuximab

Substanzen

Serum Albumin

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567 , Japan. yoshitomo-0225@outlook.com.
  • Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567 , Japan.
  • Department of Medical Oncology, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.

Zitieren

APA

Yanagimoto, Y., Yamamoto, K., Yamamoto, K., Masuike, Y., Ushimaru, Y., Omori, T., Sakai, D., Kudo, T., Matsuura, N., Sugase, T., Kanemura, T., Mori, R., Kubo, M., Fukuda, Y., Kitakaze, M., Komatsu, H., Miyo, M., Sueda, T., Nishimura, J., …, & Miyata, H. (2026). Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04927-4

Vancouver

Yanagimoto Y, Yamamoto K, Yamamoto K, Masuike Y, Ushimaru Y, Omori T, et al. Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04927-4

BibTeX
@article{Yanagimoto2026,
  author = {Yanagimoto, Yoshitomo and Yamamoto, Kazuyoshi and Yamamoto, Kei and Masuike, Yasunori and Ushimaru, Yuki and Omori, Takeshi and Sakai, Daisuke and Kudo, Toshihiro and Matsuura, Norihiro and Sugase, Takahito and Kanemura, Takashi and Mori, Ryota and Kubo, Masahiko and Fukuda, Yasunari and Kitakaze, Masatoshi and Komatsu, Hisateru and Miyo, Masaaki and Sueda, Toshinori and Nishimura, Junichi and Kagawa, Yoshinori and Goto, Kunihito and Kobayashi, Shogo and Miyata, Hiroshi},
  title = {Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04927-4}
}
Kostenlos starten →